A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers., azide free, Blogging, elisa, Goat, Hamster, Mammal, Mink, Mouse, Multiplexed shotgun genotyping for rapid and efficient genetic mapping., NGS QC Toolkit: a toolkit for quality control of next generation sequencing data., Opossum, Orangutan, pcr, Pig, Pigeon, Plant, Rat, Yeast

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.

Assessment of clonality, marker identification and measurement of minimal residual illness (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms utilizing next-generation sequencing (NGS) is presently below intensive improvement to be used in scientific diagnostics. So far, nevertheless, there’s a lack of appropriate high quality control (QC) choices with regard to standardisation and high quality metrics to make sure strong scientific software of such approaches. The EuroClonality-NGS Working Group has due to this fact established two varieties of QCs to accompany the NGS-based IG/TR assays.

First, a central polytarget QC (cPT-QC) is used to watch the primer efficiency of every of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into every affected person DNA pattern to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having built-in these two reference requirements in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS gives a whole protocol for standardised IG/TR gene rearrangement evaluation by NGS with excessive reproducibility, accuracy and precision for legitimate marker identification and quantification in diagnostics of lymphoid malignancies.

Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality evaluation, marker identification and quantification of minimal residual illness (MRD) in lymphoid neoplasms has been the main target of intense analysis, improvement and software. However, standardization and validation in a scientifically managed multicentre setting remains to be missing.
Therefore, IG/TR assay improvement and design, together with bioinformatics, was carried out throughout the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories carried out IG/TR NGS in 50 diagnostic ALL samples, and in contrast outcomes with these generated by way of routine IG/TR Sanger sequencing. A central polytarget high quality control (cPT-QC) was used to watch primer efficiency, and a central in-tube high quality control (cIT-QC) was spiked into every pattern as a library-specific high quality control and calibrator.
NGS recognized 259 (common 5.2/pattern, vary 0-14) clonal sequences vs. Sanger-sequencing 248 (common 5.0/pattern, vary 0-14). NGS primers lined doable IG/TR rearrangement varieties extra utterly in contrast with native multiplex PCR units and enabled sequencing of bi-allelic rearrangements and weak PCR merchandise. The cPT-QC confirmed excessive reproducibility throughout all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be utilized for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.